Legato Capital Management LLC Has $1.64 Million Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Legato Capital Management LLC cut its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 30.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,958 shares of the company's stock after selling 13,698 shares during the period. Legato Capital Management LLC owned approximately 0.08% of Tarsus Pharmaceuticals worth $1,642,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Amalgamated Bank boosted its holdings in Tarsus Pharmaceuticals by 30.1% in the first quarter. Amalgamated Bank now owns 1,274 shares of the company's stock worth $65,000 after purchasing an additional 295 shares in the last quarter. Northern Trust Corp boosted its holdings in Tarsus Pharmaceuticals by 12.6% in the fourth quarter. Northern Trust Corp now owns 357,616 shares of the company's stock worth $19,801,000 after purchasing an additional 40,061 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Tarsus Pharmaceuticals by 36,430.6% in the first quarter. GAMMA Investing LLC now owns 13,151 shares of the company's stock worth $676,000 after purchasing an additional 13,115 shares in the last quarter. Raymond James Financial Inc. acquired a new position in Tarsus Pharmaceuticals during the 4th quarter worth $1,107,000. Finally, Ameriprise Financial Inc. lifted its position in Tarsus Pharmaceuticals by 21.2% during the 4th quarter. Ameriprise Financial Inc. now owns 47,685 shares of the company's stock worth $2,640,000 after acquiring an additional 8,336 shares during the last quarter. 90.01% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

TARS has been the subject of a number of research analyst reports. HC Wainwright raised shares of Tarsus Pharmaceuticals to a "buy" rating and set a $72.00 target price for the company in a research report on Tuesday, May 27th. Wall Street Zen lowered shares of Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Oppenheimer initiated coverage on shares of Tarsus Pharmaceuticals in a research report on Monday, June 2nd. They set an "outperform" rating and a $75.00 target price for the company. Guggenheim boosted their target price on shares of Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Finally, The Goldman Sachs Group boosted their target price on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the stock a "neutral" rating in a research report on Monday, May 5th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $66.67.

Tarsus Pharmaceuticals Stock Performance

Shares of TARS traded down $0.94 during trading hours on Friday, reaching $41.50. 442,107 shares of the company traded hands, compared to its average volume of 549,077. The stock's fifty day moving average is $41.75 and its 200 day moving average is $46.16. The stock has a market cap of $1.74 billion, a P/E ratio of -15.20 and a beta of 0.80. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.54 and a current ratio of 5.57. Tarsus Pharmaceuticals, Inc. has a 1-year low of $20.08 and a 1-year high of $57.28.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($0.64) EPS for the quarter, beating analysts' consensus estimates of ($0.69) by $0.05. The business had revenue of $78.34 million during the quarter, compared to analyst estimates of $72.50 million. Tarsus Pharmaceuticals had a negative net margin of 44.91% and a negative return on equity of 39.72%. Equities research analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.